Robert Flavell, Md, Phd

This early-stage study is testing a new imaging agent for PET scans in men with advanced prostate cancer that has spread and stopped responding to hormone therapy. The goal is to see if this new tracer can better detect and locate cancer tumors by targeting a specific protein (CD…